ServiceNow Reports New Hire Equity Grants

ServiceNow Reports New Hire Equity Grants

SANTA CLARA, Calif.–(BUSINESS WIRE)–
ServiceNow (NYSE: NOW), the leading digital workflow company making the world work better for everyone, today announced that on Feb. 15, 2023, its Compensation Committee granted equity awards pursuant to the ServiceNow 2022 New-Hire Equity Incentive Plan. Three hundred seventy-two newly hired employees received, in the aggregate, restricted stock units representing 106,051 shares of ServiceNow common stock. These awards have a four-year vesting schedule, with vesting on a pro rata basis occurring either quarterly or biannually thereafter depending on the number of restricted stock units the new employee was granted.

About ServiceNow

ServiceNow (NYSE: NOW) makes the world work better for everyone. Our cloud-based platform and solutions help digitize and unify organizations so that they can find smarter, faster, better ways to make work flow. So employees and customers can be more connected, more innovative, and more agile. And we can all create the future we imagine. The world works with ServiceNow™. For more information, visit: www.servicenow.com.

© 2023 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.

Media Contact:

Emily Scher

408.916.6566

[email protected]

Investor Contact:

Darren Yip

925.388.7205

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Technology Artificial Intelligence Data Management

MEDIA:

Logo
Logo

Fluor Selected for Agilent Life Sciences Facility Expansion in Colorado

Fluor Selected for Agilent Life Sciences Facility Expansion in Colorado

IRVING, Texas–(BUSINESS WIRE)–Fluor Corporation (NYSE: FLR) announced today that its Advanced Technologies & Life Sciences business was selected by Agilent Technologies, Inc., to expand its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado, just north of Denver. Fluor is supporting engineering and procurement as part of the project. The total project value is $725 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005795/en/

Fluor Selected for Agilent Life Sciences Facility expansion in Colorado. (Photo: Business Wire)

Fluor Selected for Agilent Life Sciences Facility expansion in Colorado. (Photo: Business Wire)

“Speed to market is essential in the pharmaceutical industry,” said Juan Hernández, president of Fluor’s Advanced Technologies & Life Sciences business. “We will incorporate state-of-the-art engineering enhancements such as advanced automation, water reduction strategies and solvent capturing to optimize cost and construction. This enables us to fast-track the project so that Agilent can meet its global customers’ needs by getting products to market faster.”

Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability. The completed facility will provide for the synthesis, purification and lyophilization of Agilent’s custom nucleic acids therapeutics, also known as oligonucleotides or oligos.

Oligos are short deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules that serve as the active pharmaceutical ingredients for drugs targeting a growing number of diseases, including cancer, cardiovascular disease, and rare and infectious diseases.

Construction is underway with completion expected by 2026.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 41,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $12.4 billion in 2021 and is ranked 259 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 110 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

#atls

Brian Mershon

Media Relations

469.398.7621

Jason Landkamer

Investor Relations

469.398.7222

KEYWORDS: Texas Colorado United States North America Canada

INDUSTRY KEYWORDS: Manufacturing Other Science Pharmaceutical Research Urban Planning REIT Landscape Building Systems Interior Design Other Construction & Property Architecture Science Residential Building & Real Estate Commercial Building & Real Estate Construction & Property General Health Health Engineering

MEDIA:

Logo
Logo
Photo
Photo
Fluor Selected for Agilent Life Sciences Facility expansion in Colorado. (Photo: Business Wire)
Photo
Photo
Fluor selected for Agilent Life Sciences Facility expansion in Colorado. (Photo: Business Wire)

Intellinetics to Participate in Winter Wonderland Best Ideas Virtual Investor Conference

COLUMBUS, OH, Feb. 16, 2023 (GLOBE NEWSWIRE) — Intellinetics, Inc. (NYSE American: INLX), a digital transformation solutions provider, today announced that management will participate in the Winter Wonderland Best Ideas Virtual Investor Conference which will be held virtually on February 21-24, 2023. James F. DeSocio, President & CEO, and Joe Spain, CFO are scheduled to host a virtual presentation on Wednesday, February 22 at 10 a.m. ET, followed by a Q&A session. Management will also host one-on-one meetings with investors on February 23-24, 2023. All existing and prospective shareholders are invited to listen to the webcast to learn more about the Company.

DATE: Wednesday, February 22, 2023
TIME: 10 a.m. ET
LINK: https://www.webcaster4.com/Webcast/Page/2952/47667

A live audio webcast and archive of the presentation will be available using the above dedicated link. More information on the Winter Wonderland Best Ideas Virtual Investor Conference can be found at https://microcaprodeo.com/.

About Intellinetics, Inc.

Intellinetics, Inc. (NYSE American: INLX) is enabling the digital transformation. Intellinetics empowers organizations to manage, store and protect their important documents and data. The Company’s flagship solution, the IntelliCloud content management platform, delivers advanced security, compliance, workflow and collaboration features critical for highly regulated, risk-intensive markets. IntelliCloud connects documents to users and the processes they support anytime, anywhere to accelerate innovation and empower organizations to think and work in new ways. In addition, Intellinetics offers business process outsourcing (BPO), document and micrographics scanning services, and records storage. From highly regulated industries like Healthcare/Human Service Providers, K-12, Public Safety, and State and Local Governments, to businesses looking to move away from paper-based processes, Intellinetics is the all-in-one, compliant, document management solution. Intellinetics is headquartered in Columbus, Ohio. For additional information, please visit www.intellinetics.com.

Investor Contact:

FNK IR
Tom Baumann / Rob Fink
646.349.6641 / 646.809.4048
[email protected]

Joe Spain, CFO
Intellinetics, Inc.
614.921.8170
[email protected]



Cognex Reports Fourth Quarter and Full Year 2022 Results

Cognex Reports Fourth Quarter and Full Year 2022 Results

NATICK, Mass.–(BUSINESS WIRE)–Cognex Corporation (NASDAQ: CGNX) today reported financial results for 2022. Table 1 below shows selected financial data for Q4-22 compared with Q4-21 and Q3-22, and the year ended December 31, 2022 compared with the year ended December 31, 2021.

“Our fourth quarter results were in line with our guidance, but are not representative of our long-term growth expectations,” said Robert J. Willett, CEO of Cognex. “We are navigating through a challenging business environment. A few of our largest e-commerce customers have paused most of their investments. At the end of 2022, we observed slower trends across our broader factory automation business, and we have seen this carry into the beginning of 2023.”

“As we manage through this slow period, we remain focused on the long term. We have important new product launches coming up this year. These products bring powerful, easy-to-use technology which expands the number of customers we can serve. And we are investing in our sales and marketing organization to reach more of these emerging customers.”

Table 1

(Dollars in thousands, except per share amounts)

 

 

 

Revenue

 

 

 

Net Income

 

Net Income

per Diluted

Share

Non-GAAP

Net Income

per Diluted

Share*

Quarterly Comparisons

 

 

 

 

Current quarter: Q4-22

$239,433

$55,311

$0.32

$0.27

Prior year’s quarter: Q4-21

$244,065

$53,535

$0.30

$0.30

Change: Q4-21 to Q4-22

(2)%

3%

7%

(10)%

Prior quarter: Q3-22

$209,622

$33,980

$0.19

$0.21

Change: Q3-22 to Q4-22

14%

63%

68%

29%

Yearly Comparisons

 

 

 

 

Year ended December 31, 2022

$1,006,090

$215,525

$1.23

$1.31

Year ended December 31, 2021

$1,037,098

$279,881

$1.56

$1.49

Change from 2021 to 2022

(3)%

(23)%

(21)%

(12)%

 

*Non-GAAP net income per diluted share excludes a loss from fire and restructuring charges, both net of tax benefit, and discrete tax adjustments. A reconciliation from GAAP to Non-GAAP is shown in Exhibit 2 of this news release.

Summary of the Year

As a result of our challenges in 2022, annual revenue declined by 3% from a record $1.037 billion in 2021. With approximately 60% of our revenue outside the Americas, the strong U.S. dollar was a headwind for us in the year. Excluding the impact of foreign currency translation, our revenue grew 1%. Outside of our logistics business, our performance in 2022 was roughly inline on a constant currency basis with what we would expect over the long term for the remainder of our end markets.

Gross margin was 72% compared to 73% for 2021 and below the company’s mid-70% long-term target. The decline was due to elevated costs paid by Cognex to purchase scarce components because of global supply chain constraints and to replace the components lost in the fire at the company’s primary contract manufacturer in June 2022.

Operating income was 24% of revenue compared to 30% for 2021. Cognex recorded a pre-tax net loss of $20.8 million from the write-off of company assets that were destroyed or abandoned in the fire, lower annual revenue, and continued to invest in engineering and its worldwide sales force to help scale for future growth. The company also recorded pre-tax restructuring charges of $1.7 million related to the acquisition of SAC Sirius Advanced Cybernetics GmbH (“SAC”) in the fourth quarter.

Details of the Quarter

Statement of Operations Highlights – Fourth Quarter of 2022

  • Revenue decreased by 2% from Q4-21 and increased by 14% from Q3-22, or increased by 4% and 17%, respectively, in constant currency. The increase in constant currency, both year-on-year and sequentially, was largely driven by the recognition of approximately $20 million of revenue in the quarter that was delayed from the third quarter due to business disruption caused by the June fire. Otherwise, slowing large projects with a few e-commerce customers reduced revenue year-on-year, partially offset by growth in our other end markets.
  • Gross margin was 71% for Q4-22 compared to 72% for Q4-21 and 73% for Q3-22. The premiums paid by Cognex to quickly replace components through brokers following the fire reduced gross margin in the quarter, but had a minimal impact year-on-year. The unfavorable impact of currency exchange rates on revenue also reduced gross margin year-on-year.
  • Research, Development, & Engineering (RD&E) expenses increased by 5% from Q4-21 and 9% from Q3-22. The company has invested in engineering resources over the past year and stock-based compensation was higher in Q4 on both a year-on-year and sequential basis. These increases were partially offset by a favorable impact of currency exchange rates in Q4-22 as compared to both Q4-21 and Q3-22.
  • Selling, General & Administrative (SG&A) expenses decreased by 8% from Q4-21 and increased by 1% from Q3-22. The expansion of the company’s global sales and marketing organization was offset by lower incentive compensation and the timing of marketing activities. In addition, as with RD&E, Cognex benefitted from a favorable impact of currency exchange rates in Q4-22 as compared to both Q4-21 and Q3-22.
  • Cognex recorded pre-tax charges of $0.5 million and $2.9 million in Q4-22 and Q3-22, respectively, related to the June 2022 fire at the company’s primary contract manufacturer. In addition, the company recorded pre-tax charges of $1.7 million in Q4-22 related to the previously announced acquisition of SAC, a leading computational lighting company.
  • The effective tax rate was 7% in Q4-22, 8% in Q4-21, and 14% in Q3-22. All periods presented include varying tax adjustments, which are summarized in Exhibit 2. Excluding these tax adjustments, the effective tax rate was 22% in Q4-22, 8% in Q4-21, and 14% in Q3-22.

Balance Sheet Highlights – December 31, 2022

  • Cognex’s financial position as of December 31, 2022continued to be strong, with $854 million in cash and investments and no debt (following significant cash outflows to replenish inventory destroyed in the June fire). In 2022, Cognex generated $243 million in cash from operations. During the year, the company spent $204 million to repurchase its common stock and paid $46 million in dividends to shareholders. Cognex intends to continue to repurchase shares of its common stock pursuant to its existing stock repurchase program, subject to market conditions and other relevant factors.

Financial Outlook – Q1 2023

  • Cognex expects revenue for Q1-23 to be between $180 million and $200 million. This range represents a decline both year-on-year and sequentially due to lower revenue from a few large e-commerce customers and broader macroeconomic softness. As a reminder, both Q1-22 and Q4-22 included $20 million of revenue for orders that had been delayed due to supply constraints, including with respect to the June fire.
  • Gross margin for Q1-23 is expected to be in the low-70% range and reflects the significant premiums the company has paid to procure components previously destroyed by the fire.
  • The combined total of expenses for RD&E and SG&A is expected to increase by approximately 10% on a sequential basis due to investments in the company’s sales and marketing organization, merit increases, and an unfavorable impact from currency exchange rates.
  • The effective tax rate is expected to be 16%, excluding discrete tax items.

Non-GAAP Financial Measures

  • Exhibit 2 of this news release includes a reconciliation of certain financial measures from GAAP to non-GAAP. Cognex believes these non-GAAP financial measures are helpful because they allow investors to more accurately compare results over multiple periods using the same methodology that management employs in its budgeting process and in its review of operating results. Non-GAAP presentations exclude certain one-time discrete events, such as a fire loss, restructuring charges, and tax adjustments (because these costs are outside of Cognex’s normal business operations and not used by management to assess Cognex’s operating results). Cognex also uses results on a constant-currency basis as one measure to evaluate its performance and compares results between periods as if the exchange rates had remained constant period-over-period. Cognex does not intend for non-GAAP financial measures to be considered in isolation, or as a substitute for financial information provided in accordance with GAAP.
  • We estimate the tax effect of items identified in the reconciliation by applying the effective tax rate to the pre-tax amount. However, if a specific tax rate or tax treatment is required because of the nature of the item and/or the tax jurisdiction where the item was recorded, we estimate the tax effect by applying the relevant specific tax rate or tax treatment, rather than the effective tax rate.

Analyst Conference Call and Simultaneous Webcast

  • Cognex will host a conference call today at 5:00 p.m. Eastern Standard Time (EST). The telephone number is (877) 704-4573 (or (201) 389-0911 if outside the United States). A replay will begin at 8:00 p.m. EST today and will be available until 11:59 p.m. EST on Sunday, February 19, 2023. The telephone number for the replay is (877) 660-6853 (or (201) 612-7415 if outside the United States). The access code for both the live call and the replay is 1373 4893.
  • A real-time audio broadcast of the conference call or an archived recording will be accessible on the Events & Presentations page of the Cognex Investor website: https://www.cognex.com/Investor.

About Cognex Corporation

Cognex Corporation (“the Company” or “Cognex”) invents and commercializes technologies that address some of the most critical manufacturing and distribution challenges. We are a leading global provider of machine vision products and solutions that improve efficiency and quality in high-growth-potential businesses across attractive industrial end markets. Our solutions blend physical products and software to capture and analyze visual information, allowing for the automation of manufacturing and distribution tasks for customers worldwide. Machine vision products are used to automate the manufacturing or distribution and tracking of discrete items, such as mobile phones, electric vehicle batteries and e-commerce packages, by locating, identifying, inspecting, and measuring them. Machine vision is important for applications in which human vision is inadequate to meet requirements for size, accuracy, or speed, or in instances where substantial cost savings or quality improvements are maintained.

Cognex is the world’s leader in the machine vision industry, having shipped more than 4 million image-based products, representing over $10 billion in cumulative revenue, since the company’s founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit Cognex online at www.cognex.com.

Certain statements made in this news release, which do not relate solely to historical matters, are forward-looking statements. These statements can be identified by use of the words “expects,” “anticipates,” “estimates,” “potential,” “believes,” “projects,” “intends,” “plans,” “will,” “may,” “shall,” “could,” “should,” and similar words and other statements of a similar sense. These statements are based on our current estimates and expectations as to prospective events and circumstances, which may or may not be in our control and as to which there can be no firm assurances given. These forward-looking statements, which include statements regarding business and market trends, future financial performance and financial targets, the expected impact of the fire at our primary contract manufacturer’s plant on our assets, business and results of operations and related insurance recoveries, customer demand and order rates and timing of related revenue, managing supply shortages, delivery lead times, future product mix, research and development activities, sales and marketing activities, new product offerings and product development activities, capital expenditures, investments, liquidity, dividends and stock repurchases, strategic and growth plans, and estimated tax benefits and expenses and other tax matters, involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include: (1) the reliance on key suppliers, such as our primary contract manufacturer, to manufacture and deliver products; (2) the expected impact of the fire at our primary contract manufacturer’s plant on our assets, business, and results of operations and related insurance recoveries; (3) delays in the delivery of our products, the failure to meet delivery schedules, and resulting customer dissatisfaction or loss of sales; (4) the inability to obtain, or the delay in obtaining, components for our products at reasonable prices; (5) the failure to effectively manage product transitions or accurately forecast customer demand; (6) the inability to manage disruptions to our distribution centers or to our key suppliers; (7) the inability to design and manufacture high-quality products; (8) the impact, duration, and severity of the COVID-19 pandemic, particularly in China, including the availability and effectiveness of vaccines as well as government lockdowns; (9) the loss of, or curtailment of purchases by, large customers in the logistics, consumer electronics, or automotive industries; (10) information security breaches; (11) the failure to comply with laws or regulations relating to data privacy or data protection; (12) the inability to protect our proprietary technology and intellectual property; (13) the inability to attract and retain skilled employees and maintain our unique corporate culture; (14) the technological obsolescence of current products and the inability to develop new products; (15) the failure to properly manage the distribution of products and services, including the management of lead times and delivery dates; (16) the impact of competitive pressures; (17) the challenges in integrating and achieving expected results from acquired businesses; (18) potential disruptions in our business systems; (19) potential impairment charges with respect to our investments or acquired intangible assets; (20) exposure to additional tax liabilities, increases and fluctuations in our effective tax rate, and other tax matters; (21) fluctuations in foreign currency exchange rates and the use of derivative instruments; (22) unfavorable global economic conditions, including increases in interest rates and high inflation rates; (23) business disruptions from natural or man-made disasters, such as fire, or public health issues; (24) economic, political, and other risks associated with international sales and operations, including the impact of trade disputes on the economic climate in China and the war in Ukraine; (25) exposure to potential liabilities, increased costs, reputational harm, and other adverse effects associated with expectations relating to environmental, social, and governance considerations; (26) stock price volatility; and (27) our involvement in time-consuming and costly litigation or activist shareholder activities; and the other risks detailed in Cognex reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2022. You should not place undue reliance upon any such forward-looking statements, which speak only as of the date made. Cognex disclaims any obligation to update forward-looking statements after the date of such statements.

Exhibit 1

COGNEX CORPORATION

Statements of Operations

(Unaudited)

Dollars in thousands, except per share amounts

 

Three-months Ended

 

Twelve-months Ended

 

Dec. 31,

2022

 

Oct. 2,

2022

 

Dec. 31,

2021

 

Dec. 31,

2022

 

Dec. 31,

2021

 

 

 

 

 

 

 

 

 

 

Revenue

$

239,433

 

 

$

209,622

 

 

$

244,065

 

 

$

1,006,090

 

 

$

1,037,098

 

Cost of revenue (1)

 

69,869

 

 

 

57,383

 

 

 

69,082

 

 

 

284,185

 

 

 

277,271

 

Gross margin

 

169,564

 

 

 

152,239

 

 

 

174,983

 

 

 

721,905

 

 

 

759,827

 

Percentage of revenue

 

71

%

 

 

73

%

 

 

72

%

 

 

72

%

 

 

73

%

Research, development, and engineering expenses (1)

 

37,134

 

 

 

33,954

 

 

 

35,489

 

 

 

141,133

 

 

 

135,372

 

Percentage of revenue

 

16

%

 

 

16

%

 

 

15

%

 

 

14

%

 

 

13

%

Selling, general, and administrative expenses (1)

 

75,951

 

 

 

75,371

 

 

 

82,974

 

 

 

312,107

 

 

 

309,354

 

Percentage of revenue

 

32

%

 

 

36

%

 

 

34

%

 

 

31

%

 

 

30

%

Restructuring charges

 

1,657

 

 

 

 

 

 

 

 

 

1,657

 

 

 

 

Loss from fire

 

485

 

 

 

2,891

 

 

 

 

 

 

20,779

 

 

 

 

Operating income

 

54,337

 

 

 

40,023

 

 

 

56,520

 

 

 

246,229

 

 

 

315,101

 

Percentage of revenue

 

23

%

 

 

19

%

 

 

23

%

 

 

24

%

 

 

30

%

Foreign currency gain (loss)

 

2,530

 

 

 

(1,880

)

 

 

(37

)

 

 

(1,837

)

 

 

(2,270

)

Investment and other income

 

2,364

 

 

 

1,202

 

 

 

1,464

 

 

 

6,303

 

 

 

6,069

 

Income before income tax expense

 

59,231

 

 

 

39,345

 

 

 

57,947

 

 

 

250,695

 

 

 

318,900

 

Income tax expense

 

3,920

 

 

 

5,365

 

 

 

4,412

 

 

 

35,170

 

 

 

39,019

 

Net income

$

55,311

 

 

$

33,980

 

 

$

53,535

 

 

$

215,525

 

 

$

279,881

 

Percentage of revenue

 

23

%

 

 

16

%

 

 

22

%

 

 

21

%

 

 

27

%

 

 

 

 

 

 

 

 

 

 

Net income per weighted-average common and common-equivalent share:

 

 

 

 

 

 

 

 

 

Basic

$

0.32

 

 

$

0.20

 

 

$

0.30

 

 

$

1.24

 

 

$

1.59

 

Diluted

$

0.32

 

 

$

0.19

 

 

$

0.30

 

 

$

1.23

 

 

$

1.56

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common and common-equivalent shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

172,693

 

 

 

173,256

 

 

 

176,123

 

 

 

173,407

 

 

 

176,463

 

Diluted

 

173,903

 

 

 

174,327

 

 

 

179,322

 

 

 

174,869

 

 

 

179,916

 

 

 

 

 

 

 

 

 

 

 

Cash dividends per common share

$

0.070

 

 

$

0.065

 

 

$

0.065

 

 

$

0.265

 

 

$

0.245

 

Cash and investments per common share

$

4.95

 

 

$

4.73

 

 

$

5.17

 

 

$

4.95

 

 

$

5.17

 

Book value per common share

$

8.33

 

 

$

8.03

 

 

$

8.15

 

 

$

8.33

 

 

$

8.15

 

 

 

 

 

 

 

 

 

 

 

(1) Amounts include stock-based compensation expense, as follows:

 

 

 

 

 

 

 

 

 

Cost of revenue

$

503

 

 

$

468

 

 

$

380

 

 

$

2,016

 

 

$

1,345

 

Research, development, and engineering

 

5,185

 

 

 

4,209

 

 

 

3,377

 

 

 

17,693

 

 

 

13,535

 

Selling, general, and administrative

 

7,398

 

 

 

8,689

 

 

 

6,664

 

 

 

34,796

 

 

 

28,894

 

Total stock-based compensation expense

$

13,086

 

 

$

13,366

 

 

$

10,421

 

 

$

54,505

 

 

$

43,774

 

Exhibit 2

COGNEX CORPORATION

Reconciliation of Selected Items from GAAP to Non-GAAP

(Unaudited)

Dollars in thousands, except per share amounts

 

Three-months Ended

 

 

Twelve-months Ended

 

Dec. 31,

2022

 

Oct. 2,

2022

 

Dec. 31,

2021

 

 

Dec. 31,

2022

 

Dec. 31,

2021

 

 

 

 

 

 

 

 

 

 

 

Per share impact of restructuring charges and loss from fire

 

 

 

 

 

 

 

Restructuring charges

$

1,657

 

 

$

 

 

$

 

 

 

$

1,657

 

 

$

 

Tax benefit from restructuring charges

 

(523

)

 

 

 

 

 

 

 

 

 

(523

)

 

 

 

Restructuring charges, net of tax benefit

$

1,134

 

 

$

 

 

$

 

 

 

$

1,134

 

 

$

 

Per share impact of restructuring charges, net of tax benefit

$

0.01

 

 

$

 

 

$

 

 

 

$

0.01

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

Loss from fire

$

485

 

 

$

2,891

 

 

$

 

 

 

$

20,779

 

 

$

 

Tax benefit from loss on fire

 

(278

)

 

 

(928

)

 

 

 

 

 

 

(3,646

)

 

 

 

Loss from fire, net of tax benefit

$

207

 

 

$

1,963

 

 

$

 

 

 

$

17,133

 

 

$

 

Per share impact of loss from fire, net of tax benefit

 

 

 

 

0.01

 

 

 

 

 

 

 

0.10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted-average common and common-equivalent shares outstanding (GAAP)

 

173,903

 

 

 

174,327

 

 

 

179,322

 

 

 

 

174,869

 

 

 

179,916

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring charges, loss from fire, and discrete tax adjustments reconciliation

 

 

 

 

 

Operating income (GAAP)

$

54,337

 

 

$

40,023

 

 

$

56,520

 

 

 

$

246,229

 

 

$

315,101

 

Percentage of revenue (GAAP)

 

23

%

 

 

19

%

 

 

23

%

 

 

 

24

%

 

 

30

%

Restructuring charges

 

1,657

 

 

 

 

 

 

 

 

 

 

1,657

 

 

 

 

Loss from fire

 

485

 

 

 

2,891

 

 

 

 

 

 

 

20,779

 

 

 

 

Operating income (Non-GAAP)

$

56,479

 

 

$

42,914

 

 

$

56,520

 

 

 

$

268,665

 

 

$

315,101

 

Percentage of revenue (Non-GAAP)

 

24

%

 

 

20

%

 

 

23

%

 

 

 

27

%

 

 

30

%

 

 

 

 

 

 

 

 

 

 

 

Net income (GAAP)

$

55,311

 

 

$

33,980

 

 

$

53,535

 

 

 

$

215,525

 

 

$

279,881

 

Restructuring charges, net of tax benefit

 

1,134

 

 

 

 

 

 

 

 

 

 

1,134

 

 

 

 

Loss from fire, net of tax benefit

 

207

 

 

 

1,963

 

 

 

 

 

 

 

17,133

 

 

 

 

Discrete tax (benefit) expense related to stock-based compensation

 

(1,148

)

 

 

131

 

 

 

(1,148

)

 

 

 

(841

)

 

 

(11,036

)

Discrete tax (benefit) expense related to tax return filings and other

 

(7,710

)

 

 

(133

)

 

 

1,173

 

 

 

 

(4,033

)

 

 

(1,304

)

Net income (Non-GAAP)

$

47,794

 

 

$

35,941

 

 

$

53,560

 

 

 

$

228,918

 

 

$

267,541

 

Percentage of revenue (Non-GAAP)

 

20

%

 

 

17

%

 

 

22

%

 

 

 

23

%

 

 

26

%

 

 

 

 

 

 

 

 

 

 

 

Net income per diluted weighted-average common and common-equivalent share (GAAP)

$

0.32

 

 

$

0.19

 

 

$

0.30

 

 

 

$

1.23

 

 

$

1.56

 

Per share impact of Non-GAAP adjustments identified above

 

(0.05

)

 

 

0.02

 

 

 

 

 

 

 

0.08

 

 

 

(0.07

)

Net income per diluted weighted-average common and common-equivalent share (Non-GAAP)

$

0.27

 

 

$

0.21

 

 

$

0.30

 

 

 

$

1.31

 

 

$

1.49

 

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted-average common and common-equivalent shares outstanding (GAAP)

 

173,903

 

 

 

174,327

 

 

 

179,322

 

 

 

 

174,869

 

 

 

179,916

 

 

 

 

 

 

 

 

 

 

 

 

Three-months Ended

 

 

Twelve-months Ended

 

Dec. 31,

2022

 

Oct. 2,

2022

 

Dec. 31,

2021

 

 

Dec. 31,

2022

 

Dec. 31,

2021

Effective tax rate reconciliation

 

 

 

 

 

 

 

Income before income tax expense (GAAP)

$

59,231

 

 

$

39,345

 

 

$

57,947

 

 

 

$

250,695

 

 

$

318,900

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense (GAAP)

$

3,920

 

 

$

5,365

 

 

$

4,412

 

 

 

$

35,170

 

 

$

39,019

 

Effective tax rate (GAAP)

 

7

%

 

 

14

%

 

 

8

%

 

 

 

14

%

 

 

12

%

 

 

 

 

 

 

 

 

 

 

 

Tax adjustments:

 

 

 

 

 

 

 

 

 

 

Discrete tax benefit (expense) related to stock-based compensation

 

1,148

 

 

 

(131

)

 

 

1,148

 

 

 

 

841

 

 

 

11,036

 

Discrete tax benefit (expense) related to tax return filings and other

 

7,710

 

 

 

133

 

 

 

(1,173

)

 

 

 

4,033

 

 

 

1,304

 

Total tax adjustments

$

8,858

 

 

$

2

 

 

$

(25

)

 

 

$

4,874

 

 

$

12,340

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense (Non-GAAP) (1)

$

12,778

 

 

$

5,367

 

 

$

4,387

 

 

 

$

40,044

 

 

$

51,359

 

Effective tax rate (Non-GAAP) (1)

 

22

%

 

 

14

%

 

 

8

%

 

 

 

16

%

 

 

16

%

 

 

 

 

 

 

 

 

 

 

 

(1) The loss from the fire in the second and third quarters of 2022 had a tax benefit that during the quarter we accounted for as a discrete tax item. At year end, we reclassified these benefits for Non-GAAP presentation purposes, and as such we have adjusted our Non-GAAP effective tax rates for the quarters impacted by the fire loss. We previously reported a 16% Non-GAAP effective tax rate for both Q2 and Q3 and Income tax expense (Non-GAAP) of $10,306 and $6,295, respectively. Using the updated classification, these rates would have been 12% and 14% and the Income tax expense (Non-GAAP) would have been $7,866 and $5,367 in Q2 and Q3, respectively. There have been no changes to any previously reported GAAP figures.

Exhibit 3

COGNEX CORPORATION

Balance Sheets

(Unaudited)

Dollars in thousands

 

December 31, 2022

 

December 31, 2021

Assets

 

 

 

Cash and investments

$

854,250

 

$

907,364

Accounts receivable

 

125,417

 

 

 

130,348

 

Inventories

 

122,480

 

 

 

113,102

 

Property, plant, and equipment

 

79,714

 

 

 

77,546

 

Operating lease assets

 

37,682

 

 

 

23,157

 

Goodwill and intangible assets

 

255,044

 

 

 

253,601

 

Deferred tax assets

 

407,241

 

 

 

418,570

 

Other assets

 

76,312

 

 

 

79,974

 

 

 

 

 

Total assets

$

1,958,140

 

 

$

2,003,662

 

 

 

 

 

Liabilities and Shareholders’ Equity

 

 

 

Accounts payable and accrued expenses

$

120,338

 

 

$

136,483

 

Deferred revenue and customer deposits

 

40,787

 

 

 

35,743

 

Operating lease liabilities

 

39,752

 

 

 

25,581

 

Income taxes

 

67,003

 

 

 

66,517

 

Deferred tax liabilities

 

249,961

 

 

 

293,769

 

Other liabilities

 

1,905

 

 

 

15,476

 

Shareholders’ equity

 

1,438,394

 

 

 

1,430,093

 

 

 

 

 

Total liabilities and shareholders’ equity

$

1,958,140

 

 

$

2,003,662

 

 

Nathan McCurren

Head of Investor Relations

+1 508-654-1755

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Engineering Machine Tools, Metalworking & Metallurgy Manufacturing

MEDIA:

Logo
Logo

Cognex Announces Appointment of New Board Member and Retirement of Two Board Members

Cognex Announces Appointment of New Board Member and Retirement of Two Board Members

NATICK, Mass.–(BUSINESS WIRE)–Cognex Corporation (NASDAQ: CGNX) today announced the appointment of Angelos Papadimitriou to Cognex’s Board of Directors, effective on February 17, 2023. Papadimitriou will serve on the Audit Committee.

“We are excited for Angelos to join our board,” said Anthony Sun, Chairman of Cognex. “His executive leadership experience, expertise in packaging machinery and industrial automation industries and European and international markets, and experience as an institutional investor will be a valuable asset to Cognex. We look forward to his insight and guidance.”

In addition, on February 15, 2023, Directors Theodor Krantz and Patrick Alias each informed the Company of his decision to retire from the Company’s Board of Directors, effective May 3, 2023 upon completion of his current term as a director. Mr. Alias will remain as an employee of the Company in an advisory role. Following the departures of Mr. Krantz and Mr. Alias, the number of directors on the Board will be decreased from nine to seven.

About Angelos Papadimitriou

Angelos Papadimitriou, 56, currently serves as Chairman of the Board of Directors of Athena Ventures, an early-stage venture fund. From August 2020 to February 2021, Mr. Papadimitriou was the Co-Chief Executive Officer of Pirelli & C. S.p.A., a public company listed on the Milan Stock Exchange. Mr. Papadimitriou previously led Coesia S.p.A., a group of global industrial and packaging solutions companies as their Chief Executive Officer for ten years. Prior to that, Mr. Papadimitriou spent over fifteen years in the pharmaceutical industry, including as Senior Vice President for Italy and Southeast Europe at Glaxosmithkline. Mr. Papadimitriou currently serves as a director of Humanitas, a privately-held network of teaching and research hospitals and Dompé Farmaceutici S.p.A., a privately-held biopharmaceutical company. Mr. Papadimitriou holds an MBA from Harvard Business School and a Bachelor of Arts in Computer Science and Business Economics from Brown University.

About Cognex

Cognex Corporation (“the Company” or “Cognex”) invents and commercializes technologies that address some of the most critical manufacturing and distribution challenges. We are a leading global provider of machine vision products and solutions that improve efficiency and quality in high-growth-potential businesses across attractive industrial end markets. Our solutions blend physical products and software to capture and analyze visual information, allowing for the automation of manufacturing and distribution tasks for customers worldwide. Machine vision products are used to automate the manufacturing or distribution and tracking of discrete items, such as mobile phones, electric vehicle batteries and e-commerce packages, by locating, identifying, inspecting, and measuring them. Machine vision is important for applications in which human vision is inadequate to meet requirements for size, accuracy, or speed, or in instances where substantial cost savings or quality improvements are maintained.

Cognex is the world’s leader in the machine vision industry, having shipped more than 4 million image-based products, representing over $10 billion in cumulative revenue, since the company’s founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit Cognex online at www.cognex.com.

Certain statements made in this news release, which do not relate solely to historical matters, are forward-looking statements. These statements can be identified by use of the words “expects,” “anticipates,” “estimates,” “believes,” “projects,” “intends,” “plans,” “will,” “may,” “shall,” “could,” “should,” and similar words and other statements of a similar sense. These statements are based on our current estimates and expectations as to prospective events and circumstances, which may or may not be in our control and as to which there can be no firm assurances given. These forward-looking statements—which may include statements regarding business and market trends; future financial performance; growth opportunities; and strategic plans—involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include: (1) the inability to attract and retain skilled employees and directors and maintain our unique corporate culture; (2) the failure to effectively manage our growth; and (3) the impact of competitive pressures; and the other risks detailed in Cognex reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2022. You should not place undue reliance upon any such forward-looking statements, which speak only as of the date made. Cognex disclaims any obligation to update forward-looking statements after the date of such statements.

Nathan McCurren

Investor Relations

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Technology Manufacturing Other Technology Software Other Manufacturing Artificial Intelligence Hardware

MEDIA:

Logo
Logo

Cognex Declares Quarterly Cash Dividend

Cognex Declares Quarterly Cash Dividend

NATICK, Mass.–(BUSINESS WIRE)–Cognex Corporation (NASDAQ: CGNX) today announced that the company’s Board of Directors declared a quarterly cash dividend of $0.07 per share, payable on March 17, 2023 to all shareholders of record at the close of business on March 3, 2023.

About Cognex

Cognex Corporation (“the Company” or “Cognex”) invents and commercializes technologies that address some of the most critical manufacturing and distribution challenges. We are a leading global provider of machine vision products and solutions that improve efficiency and quality in high-growth-potential businesses across attractive industrial end markets. Our solutions blend physical products and software to capture and analyze visual information, allowing for the automation of manufacturing and distribution tasks for customers worldwide. Machine vision products are used to automate the manufacturing or distribution and tracking of discrete items, such as mobile phones, electric vehicle batteries and e-commerce packages, by locating, identifying, inspecting, and measuring them. Machine vision is important for applications in which human vision is inadequate to meet requirements for size, accuracy, or speed, or in instances where substantial cost savings or quality improvements are maintained.

Cognex is the world’s leader in the machine vision industry, having shipped more than 4 million image-based products, representing over $10 billion in cumulative revenue, since the company’s founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit Cognex online at www.cognex.com.

Nathan McCurren

Head of Investor Relations

+1 508-654-1755

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Other Manufacturing Technology Other Technology Manufacturing Software Machinery Batteries Hardware Consumer Electronics

MEDIA:

Logo
Logo

Teekay Group to Announce Fourth Quarter and Annual 2022 Earnings Results on February 23, 2023

HAMILTON, Bermuda, Feb. 16, 2023 (GLOBE NEWSWIRE) — Teekay Corporation (Teekay) (NYSE:TK) and Teekay Tankers Ltd. (Teekay Tankers) (NYSE:TNK) plan to release their financial results for the fourth quarter and annual 2022 before market open on Thursday, February 23, 2023.

Teekay Tankers plans to host a conference call on Thursday, February 23, 2023 at 11:00 a.m. (ET) to discuss its results for the fourth quarter and annual 2022. All shareholders and interested parties are invited to listen to the live conference call by choosing from the following options:

  • By dialing (888) 254-3590, or (647) 484-0478 if outside of North America, and quoting conference ID code 1561632.
  • By accessing the webcast, which will be available on Teekay’s website at www.teekay.com (the archive will remain on the website for a period of one year).

Accompanying Teekay Tankers Fourth Quarter and Fiscal 2022 Earnings Presentation will also be available at www.teekay.com in advance of the conference call start time.

About Teekay

Teekay is a leading provider of international crude oil and other marine transportation services. Teekay provides these services directly and through its controlling ownership interest in Teekay Tankers Ltd. (NYSE: TNK), one of the world’s largest owners and operators of mid-sized crude tankers. The consolidated Teekay entities manage and operate total assets under management of approximately $2 billion, comprised of approximately 65 conventional tankers and other marine assets. With offices in 8 countries and approximately 2,500 seagoing and shore-based employees, Teekay provides a comprehensive set of marine services to the world’s leading energy companies and the Australian government.

Teekay’s common stock is listed on the New York Stock Exchange where it trades under the symbol “TK”.

About Teekay Tankers

Teekay Tankers currently has a fleet of 44 double-hull tankers (including 25 Suezmax tankers, 10 Aframax tankers and nine LR2 product tankers), and also has seven time chartered-in tankers. Teekay Tankers’ vessels are typically employed through a mix of short- or medium-term fixed-rate time charter contracts and spot tanker market trading. Teekay Tankers also owns a Very Large Crude Carrier (VLCC) through a 50 percent-owned joint venture. In addition, Teekay Tankers owns a ship-to-ship transfer business that performs full service lightering and lightering support operations in the U.S. Gulf and Caribbean. Teekay Tankers was formed in December 2007 by Teekay Corporation as part of its strategy to expand its oil tanker business.

Teekay Tankers’ Class A common stock trades on the New York Stock Exchange under the symbol “TNK.”

For Teekay Investor Relations

enquiries contact:

E-mail: [email protected]

For Teekay Tankers Investor Relations

enquiries contact:

E-mail: [email protected]

Website: www.teekay.com



PDC Energy Declares Increased Quarterly Cash Dividend on Common Shares and Announces $750 Million Increase to Share Buyback Authorization

DENVER, Feb. 16, 2023 (GLOBE NEWSWIRE) — PDC Energy, Inc. (“PDC” or the “Company”) (Nasdaq:PDCE) announced today that its Board of Directors declared an increase to its quarterly cash dividend from $0.35 to $0.40 per share on PDC’s outstanding common stock. The dividend is payable on March 16, 2023, to stockholders of record at the close of business on March 2, 2023. This marks the second consecutive annual increase since implementing the dividend in 2021.

PDC also announced that the Board of Directors approved an incremental $750 million dollars to the Company’s existing $1.25 billion share repurchase program, bringing the total authorization to $2.0 billion. The Company remains committed to returning a minimum of 60 percent of its annual post base dividend adjusted free cash flow (FCF) to shareholders through the Company’s share repurchase program and a year-end special dividend, if needed.

About PDC Energy, Inc.

PDC Energy, Inc. is a domestic independent exploration and production company that acquires, explores and develops properties for the production of crude oil, natural gas and NGLs, with operations in the Wattenberg Field in Colorado and Delaware Basin in west Texas. Its operations in the Wattenberg Field are focused in the horizontal Niobrara and Codell plays and its Delaware Basin operations are primarily focused in the horizontal Wolfcamp zones.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (“Securities Act”), Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”), and the United States (“U.S.”) Private Securities Litigation Reform Act of 1995 regarding PDC’s business and prospects, including future anticipated return of capital plans. All statements other than statements of historical fact included in and incorporated by reference into this release are “forward-looking statements”.

PDC cautions you not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statements in order to reflect any event or circumstance occurring after the date of this report or currently unknown facts or conditions or the occurrence of unanticipated events. The forward-looking statements are subject to numerous risks and uncertainties; factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include those discussed in the “Risk Factors” section of PDC’s Annual Report on Form 10-K for the year ended December 31, 2021, which discussion is incorporated herein by reference. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contacts: Aaron Vandeford
  Director Investor Relations
  303-381-9493
  [email protected]



Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023.

The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology

Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.



Contacts:

Carly Scaduto
Senior Director, Media Relations
[email protected]
+1 314-368-5189

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

Fiscal Calendar Year Changes from June to December Year End

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022.

“The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company’s core brachytherapy business lack of orders from our largest customer and post-COVID recovery efforts resulted in a sales decline. We will continue to advocate for awareness of the long-term benefits of Cesium-131 brachytherapy treatment across respective indications and in particular for prostate cancer as an alternative to radical prostatectomy,” said Perspective Therapeutics CEO Thijs Spoor.

“Looking forward, as we advance the mission of the combined companies, we are introducing a new wave of alpha-particle radiotherapy that represents an entirely new class of theranostics developed to treat a broad class of cancers. Strong scientific fundamentals continue to build a mounting body of supporting evidence for Perspective’s targeted alpha therapy (TAT) precision oncology approach to changing the treatment landscape for melanoma and neuroendocrine tumors. Perspective Therapeutics’ two-step approach utilizing targeted peptides to diagnose and deliver extremely powerful radiotherapy holds the promise of delivering precision targeted medicine from the inside out. We firmly believe that by improving efficacy and reducing toxicity across a broad class of cancer treatments, we will not only unlock shareholder value in the Company but also transform the radiotherapy treatment paradigm for patients. I am confident the best is yet to come,” concluded Perspective Therapeutics CEO Thijs Spoor.

Development Highlights in 2022 for the targeted alpha therapy (TAT) subsidiary Viewpoint Molecular Targeting

Melanoma

  • Based off of extraordinary pre-clinical results utilizing combination therapies published as, Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma, December 2021, (Li. et al) the Company received an additional $2 million grant awarded from NCI to pursue combination therapies
  • Closed out first human imaging study: (“TIMAR1”) study at Mayo Clinic in metastatic melanoma
    • No safety concerns observed during first human evaluation of compound in the imaging only setting
  • Received safe to proceed from U.S. FDA for imaging and therapy study using 203Pb/212Pb
  • Publication of TIMAR1 study results expected later this year
  • First patients enrolled in melanoma study expected middle of this year

Neuroendocrine

  • Extraordinary head-to-head results seen in a pre-clinical model comparing a-NET to standard of care
  • [212Pb]VMT-α-NET granted U.S. FDA Fast Track designation for the treatment of neuroendocrine tumors
  • Received safe to proceed letter from U.S. FDA for imaging and therapy study using 203Pb/212Pb
  • Additional human imaging in compassionate use achieved
  • Investigator initiated human studies of the diagnostic agent initiated in the US, no safety issues observed
  • First patients treated in compassionate use setting; no safety issues observed to date

Isotopes / Generator

  • Enabling technology for daily supply of 212Pb which allows physicians globally to reliably access therapeutic isotope
  • Major collaborations with University of Alberta and University of Alabama for reliable production of pure isotope, publication in leading journal
  • Supported 203Pb user group to allow the medical community to learn how to adopt and use 203Pb which has now been taken over by the DOE

Pipeline

  • Significantly increased R&D productivity, shortening time from target identification to lead candidate
  • Developed strong pipeline of peptide derived targets across multiple solid tumor targets

Financial Results for Isoray, Inc. for the Quarter Ended December 31, 2022

Revenue for the three months ended December 31, 2022 decreased 35% to $1.84 million versus $2.82 million in the prior year comparable period. The year over year decline in revenue was the result of sales to treat prostate cancer which declined 50% year over year primarily due to a lack of orders from our largest customer during the quarter. Prostate brachytherapy represented 58% of total revenue for the three months ended December 31, 2022 compared to 76% in the prior year comparable period. Non-prostate brachytherapy revenue increased 14% versus the prior year comparable period. The majority of non-prostate brachytherapy revenue in the three-month period was comprised of sales to treat brain cancer, including sales of GammaTile® Therapy.

Gross profit as a percentage of revenues was 22.0% for the three months ended December 31, 2022 versus 43.3% in the prior year comparable period. Gross profit decreased to $0.40 million versus $1.22 million in the comparable year ago quarter. The year over year decrease was primarily the result of the decrease in core prostate sales resulting from lower order volumes.

Total operating expenses in the three months ended December 31, 2022 were $3.70 million compared to $2.86 million in the prior year period. Total research and development expenses increased 15% versus the prior year comparable period. The increase in research and development expenses was primarily the result of increased payroll expense due to annual merit increases and travel related expenses versus the prior year comparable period.

Sales and marketing expenses increased 16% versus the prior year comparable period. The increase in sales and marketing expenses was driven primarily by an increase in travel, conventions, and tradeshow expenses, increased consulting expenses, and increased payroll and benefits expense due to annual merit increases versus the prior year comparable period. General and administrative expenses increased 35% versus the prior year comparable period. The increases in general and administrative expenses were primarily the result of legal, proxy solicitation and other public company related expenses associated with the merger with Viewpoint Molecular Targeting, Inc. Also contributing to the increase were payroll and benefits expense due to annual merit increases and increased travel. In addition, the Company wrote-off some software implementation costs as the Company will change certain systems due to the merger.

The net loss for the three months ended December 31, 2022 was $2.90 million or ($0.02) per basic and diluted share versus a net loss of $1.60 million or ($0.01) per basic and diluted share in the comparable prior year period. Basic and diluted per share results are based on weighted average shares outstanding of approximately 142.1 million for the three months ended December 31, 2022 versus 142.0 million in the comparable prior year period.

Cash, cash equivalents, and short-term investments as of December 31, 2022, totaled $43.8 million and the Company had no long-term debt. Stockholders’ equity totaled $55.0 million.

Subsequent Events

On February 3, 2023, Isoray, Inc. completed the merger with privately held Viewpoint Molecular Targeting, Inc. Isoray, Inc. amended its Certificate of Incorporation on February 14, 2023, to change its name to Perspective Therapeutics, Inc. The Company currently trades on the NYSE American as Isoray, Inc. under ticker symbol ISR, which is expected to change to Perspective Therapeutics, Inc. with the ticker symbol of CATX on February 21, 2023.

On January 31, 2023, the Board of Directors of Isoray, Inc. approved a change in the fiscal year end of the Company from June 30 to December 31. The Company’s fiscal year will now be the calendar year pursuant to such change. The Company will file a transition report on Form 10-KT covering the transition period from July 1, 2022, to December 31, 2022 and expects to do so by May 2023. As a result, the Company will not be filing a Form 10-Q for the three-month period ended December 31, 2022 but expects to file a Form 10-Q for the three-month period ending March 31, 2023 by mid May 2023.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., formerly known as Isoray, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

Statements in this news release about the business and milestones achieved by Viewpoint Molecular Targeting in calendar year 2022 were accomplished prior to its merger with Isoray and are not reflected in and have nothing to do with the performance of Isoray, Inc. (now Perspective Therapeutics, Inc.) in the quarter ending December 31, 2022. Statements in this news release about Perspective Therapeutics, Inc.’s (“Perspective”) and its wholly-owned subsidiary Viewpoint Molecular Targeting, Inc.’s (“Viewpoint,” and together with Perspective, the “Company”) future expectations, including: the ticker symbol change, the anticipated synergies and benefits of the merger between Perspective and Viewpoint; the anticipated pipeline of the Company’s programs and products; expectations about the Company’s addressable markets; the functionality and capabilities of the Company’s therapies including its targeted alpha-particle radiotherapy; the potential size of the commercial market for the Company’s treatment programs; the Company’s expectations, beliefs, intentions, and strategies regarding the future; and all other statements in this news release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing the Company of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether and to what extent the anticipated benefits of the merger are realized; the ability to raise ongoing capital to fund added costs of research and development related to the Company’s business; the ability of the Company to manage growth and successfully integrate its businesses; whether the Company can maintain its key employees; the risk that the merger disrupts current plans and operations; the outcome of any legal proceedings that may be instituted against the Company following consummation of the merger; whether the results of studies of targeted alpha-particle radiotherapy or using Cesium-131 in conjunction with immunotherapy combinations are conducted on the anticipated timelines or are successful; whether the Company’s anticipated product pipeline is achieved; whether additional studies are released that reinforce the results of the studies discussed in this presentation; whether the anticipated benefits of the Company’s therapies are realized; training and use of the Company’s products; market acceptance and recognition of the Company’s products; the Company’s ability to enforce its intellectual property rights; whether ongoing patient results are favorable and in line with the conclusions of clinical studies and initial patient results; successful completion of future research and development activities; whether we, our distributors, and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell, and use our products in their various forms; the procedures and regulatory requirements mandated by the FDA for animal trials, human trials, clinical studies, Phase I and II approvals and 510(k) approval and reimbursement codes; changes in applicable laws and regulations; and other risks detailed from time to time in the Company’s reports filed with the SEC.

Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For more information regarding risks and uncertainties that could affect the Company’s results of operations or financial condition, please review the definitive Proxy Statement filed on November 7, 2022, and our Form 10-K filed on September 28, 2022, with the SEC.

Isoray, Inc. and Subsidiaries 
Consolidated Balance Sheets  (Unaudited)
(In thousands, except shares) 

    December 31,     June 30,  
    2022     2022  
ASSETS                
Current assets:                
Cash and cash equivalents   $ 20,993     $ 55,890  
Short-term investments     22,764        
Accounts receivable, net     1,363       1,608  
Inventory     1,618       1,396  
Note Receivable     6,088        
Prepaid expenses and other current assets     727       435  
                 
Total current assets     53,553       59,329  
                 
Property and equipment, net     1,891       1,976  
Right of use asset, net     378       512  
Restricted cash     182       182  
Inventory, non-current     2,187       2,333  
Other assets, net     86       107  
                 
Total assets   $ 58,277     $ 64,439  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                 
Current liabilities:                
Accounts payable and accrued expenses   $ 1,341     $ 966  
Lease liability     276       268  
Accrued protocol expense     253       150  
Accrued radioactive waste disposal     129       120  
Accrued payroll and related taxes     212       509  
Accrued vacation     285       253  
                 
Total current liabilities     2,496       2,266  
Non-current liabilities:                
Lease liability, non-current     116       256  
Asset retirement obligation     657       640  
                 
Total liabilities     3,269       3,162  
Commitments and contingencies                
                 
Stockholders’ equity:                
Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding            
Common stock, $.001 par value; 200,000,000 shares authorized; 142,112,766 and 142,040,266 shares issued and outstanding     142       142  
Additional paid-in capital     160,432       159,732  
Accumulated deficit     (105,566 )     (98,597 )
                 
Total stockholders’ equity     55,008       61,277  
                 
Total liabilities and stockholders’ equity   $ 58,277     $ 64,439  

Isoray, Inc. and Subsidiaries 
Consolidated Statements of Operations  (Unaudited) 
(Dollars and shares in thousands, except for per-share amounts) 

    Three months ended  
    December 31,  
    2022     2021  
                 
Sales, net   $ 1,835     $ 2,816  
Cost of sales     1,432       1,596  
Gross profit     403       1,220  
                 
Operating expenses:                
Research and development     613       535  
Sales and marketing     814       702  
General and administrative     2,179       1,618  
Loss on equipment disposals     98        
Total operating expenses     3,704       2,855  
                 
Operating loss     (3,301 )     (1,635 )
                 
Non-operating income:                
Interest income     400       31  
Non-operating income     400       31  
                 
Net loss   $ (2,901 )   $ (1,604 )
                 
Basic and diluted loss per share   $ (0.02 )   $ (0.01 )
                 
Weighted average shares used in computing net loss per share:                
Basic and diluted     142,113       141,955  



Contacts
Legacy Isoray Investor Relations: Mark Levin (501) 255-1910
Legacy Viewpoint Molecular Targeting Investor Relations: Chuck Padala (917) 741-7792
Media and Public Relations: Sharon Schultz (302) 539-3747